Sobi announces a new research collaboration on the development of Gamifant in sepsis, which is to be presented at the ISICEM congress: Stockholm Thursday, March 20, 2025, 12:00 Hr ...

The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS ...

Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...

Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Emapalumab-Izsg is under the FDA’s Priority Review for hemophagocytic lymphohistiocytosis/macrophage activation syndrome in Still disease.

Swedish Orphan Biovitrum AB. The US Food and Drug Administration has accepted Sobi’s supplemental biologics licence application for Gamifant (emapalumab-Izsg) for haemophagocytic lymphohistiocytosis ...

A Prescription Drug User Fee Act target date of June 27, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...

Use of intravascular ultrasound guidance during endovascular treatment is associated with improved outcomes in patients with LEAD. Intravascular ultrasound (IVUS) guidance is associated with improved ...

"There is no approved therapy for HLH/MAS today. Gamifant® (emapalumab-Izsg) selectively neutralizes interferon gamma (IFN-?), a key driver of hyperinflammation, and if approved, may also help ...

"There is no approved therapy for HLH/MAS today. Gamifant® (emapalumab-Izsg) selectively neutralizes interferon gamma (IFN-γ), a key driver of hyperinflammation, and if approved, may also help ...